Last reviewed · How we verify
Intravenous Infusion
Unable to determine specific mechanism without a named drug product.
At a glance
| Generic name | Intravenous Infusion |
|---|---|
| Also known as | levodopa, Medicine, Matching Placebo, Paracetamol, PCA |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Intravenous infusion is a route of administration rather than a specific drug. Without a brand name, generic name, or molecular target, the mechanism cannot be characterized. AstraZeneca manufactures multiple IV infusion products across different therapeutic areas.
Approved indications
Common side effects
Key clinical trials
- A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (PHASE1)
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) (PHASE1, PHASE2)
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- AAV8-hCocH for Cocaine Use Disorder (PHASE1)
- DDAVP for Pituitary Adenoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Infusion CI brief — competitive landscape report
- Intravenous Infusion updates RSS · CI watch RSS
- AstraZeneca portfolio CI